secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001437749-24-016041
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma Q3 net income $0.3M vs $16k YoY; revenue flat at $13.1M
----------------------------------------------------------------------------

- Quarterly revenue $13.1M (flat YoY); operating income $0.4M vs $44k prior year.
- Net income $0.3M ($0.01 diluted EPS) vs $16k ($0.00) in Q3 2023.
- Nine-month revenue $37.6M (down 0.3% YoY); net loss $0.2M ($0.01 loss per share).
- Two largest contract manufacturing customers represent ~90% of total revenue; management plans to expand customer base by FY2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774924016041/0001437749-24-016041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774924016041/inbp20240509_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-016041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer